Genbioma key facts
as of Oct 2026- Developer of postbiotic therapeutics designed to support metabolic health in conditions related to glucose regulation, weight management, and cardiovascular function.
- Genbioma is valued at approximately $1.9M as of Oct 2026 (last reported valuation).
- It has raised $1.5M.
- Notable investors include Clave (Pamplona), Sociedad de Desarrollo de Navarra, CaixaBank, KMZERO (Valencia), Scale the Impact — 8 tracked in total.
- Status: Privately Held (backing).
Genbioma's last reported valuation, Jan 2021. Nothing priced has surfaced since.
- ·Watch Genbioma: the Monday email on marks, rounds and moves
Genbioma funding rounds
No funding rounds for Genbioma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Genbioma valuation
Genbioma's last reported valuation was $1.9 million in Jan 2021. No priced round, secondary trade or fund mark has surfaced since.
Genbioma investors
8 investors are on record for Genbioma, including Clave (Pamplona), Sociedad de Desarrollo de Navarra, CaixaBank and KMZERO (Valencia).
About Genbioma
Developer of postbiotic therapeutics designed to support metabolic health in conditions related to glucose regulation, weight management, and cardiovascular function. The company offers microbiome research capabilities, postbiotic development, and rapid bacterial strain assessment using a C. elegans-based model, enabling healthcare and life sciences organizations to identify and develop candidates with relevant metabolic health effects more efficiently.
- Sector
- Healthcare
- HQ
- Noáin, Spain
- Founded
- 2019
- Employees
- 7
- Website
- genbioma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.